Abstract
Histone deacetylase inhibitors (HDACi) are used as therapeutics for several B cell-derived malignancies. Furthermore, they have been shown to modulate the response of the immune system, like the B cell function. HDACi treatment affects differentiation, proliferation, and survival of B cells. Here we describe how to investigate the effects of HDACi treatment on naïve B cells regarding class-switch recombination (CSR) in vitro using flow cytometry.
Keywords:
Class switch recombination; Flow cytometry; HDAC inhibition; Magnetic separation; Naïve B lymphocytes.
MeSH terms
-
Animals
-
B-Lymphocytes / cytology
-
B-Lymphocytes / drug effects*
-
B-Lymphocytes / immunology
-
Benzamides / pharmacology
-
Carbazoles / pharmacology
-
Cell Cycle
-
Cell Differentiation / drug effects
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Cytokines / pharmacology
-
Flow Cytometry / methods
-
Histone Deacetylase Inhibitors / pharmacology*
-
Histone Deacetylases / genetics
-
Histone Deacetylases / immunology*
-
Hydroxamic Acids / pharmacology
-
Immunoglobulin Class Switching / drug effects*
-
Immunoglobulins / genetics
-
Immunomagnetic Separation / methods*
-
Indoles / pharmacology
-
Lipopolysaccharides / pharmacology
-
Mice
-
Mice, Inbred C57BL
-
Panobinostat
-
Primary Cell Culture
-
Pyridines / pharmacology
-
Recombination, Genetic / drug effects*
-
Recombination, Genetic / immunology
Substances
-
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
-
Benzamides
-
Carbazoles
-
Cytokines
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Immunoglobulins
-
Indoles
-
Lipopolysaccharides
-
Pyridines
-
entinostat
-
Panobinostat
-
Histone Deacetylases